Comparative effectiveness of tofacitinib and adalimumab in axial spondyloarthritis: A real-world clinical context multicenter study
J Clin Rheumatol 2024 doi 10.1097/RHU.0000000000002069
This study by Goswami, et al. found that tofacitinib showed comparable effectiveness with adalimumab in axSpA patients at the sixth month.
Goswami, et al. aimed in this historical study to compare the effectiveness and tolerability of tofacitinib with adalimumab, in axSpA patients, across a real-world clinical setting via, case records of consecutive patients with AS or nr-axSpA treated with tofacitinib or adalimumab.